Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): New US investor joins Series C financing of Karolinska Development's portfolio company Ap...

STOCKHOLM, February 27, 2019. Karolinska Development's portfolio company Aprea
Therapeutics announces today that funds managed by Janus Henderson Investors
has joined its Series C financing as a new investor, raising the total amount
of the financing from EUR 50 to EUR 55 million.

Janus Henderson Investors joins the financing round closed in November, 2018
and led by Redmile Group, with participation by Rock Springs Capital and
existing investors: 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset
Management and Karolinska Development AB.

"Aprea Therapeutics has a unique position as it has shown very convincing
clinical evidence for its novel anticancer therapies targeting the p53 tumor
suppressor protein. The addition of Janus to the investor group is an
acknowledgment of the development plan for APR-246 and further strengthens
Aprea's ability to advance its clinical strategy", comments Viktor Drvota,
CEO of Karolinska Development.

Proceeds from the financing will be used to advance the clinical development
of APR-246, a first-in-class anticancer agent that reactivates mutated p53
tumor suppressor protein. Aprea has commenced a Phase 3 clinical study in
myelodysplastic syndromes (MDS) and has completed enrollment in a Phase Ib/II
clinical trial in p53 mutated high-risk myelodysplastic syndromes (MDS) and
oligoblastic acute myeloid leukemia (AML) with APR-246 and azacitidine.
Additional studies in MDS and AML are underway and in planning with other
approved agents.

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:


About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global

For more information, please

Karolinska Development News Aprea 190227

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.